Amicogen, Inc.

KOSDAQ:A092040 Stock Report

Market Cap: ₩215.7b

Amicogen Dividends and Buybacks

Dividend criteria checks 0/6

Amicogen does not currently pay a dividend.

Key information

0%

Dividend yield

-32.6%

Buyback Yield

Total Shareholder Yield-32.6%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per share₩25.000
Payout ratio0%

Recent dividend and buyback updates

No updates

Recent updates

Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price

Nov 11
Revenues Working Against Amicogen, Inc.'s (KOSDAQ:092040) Share Price

Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding

Jun 27
Little Excitement Around Amicogen, Inc.'s (KOSDAQ:092040) Revenues As Shares Take 27% Pounding

Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Jun 19
Does Amicogen (KOSDAQ:092040) Have A Healthy Balance Sheet?

Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

Mar 21
Amicogen, Inc. (KOSDAQ:092040) Held Back By Insufficient Growth Even After Shares Climb 39%

With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting

Mar 23
With EPS Growth And More, Amicogen (KOSDAQ:092040) Is Interesting

Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?

Mar 05
Should Amicogen (KOSDAQ:092040) Be Disappointed With Their 24% Profit?

Is Amicogen (KOSDAQ:092040) A Risky Investment?

Feb 15
Is Amicogen (KOSDAQ:092040) A Risky Investment?

What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?

Jan 31
What Kind Of Investors Own Most Of Amicogen, Inc. (KOSDAQ:092040)?

Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Jan 14
Could The Market Be Wrong About Amicogen, Inc. (KOSDAQ:092040) Given Its Attractive Financial Prospects?

Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Dec 30
Amicogen (KOSDAQ:092040) Is Growing Earnings But Are They A Good Guide?

Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Dec 15
Is Now The Time To Put Amicogen (KOSDAQ:092040) On Your Watchlist?

Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

Nov 30
Did You Miss Amicogen's (KOSDAQ:092040) 37% Share Price Gain?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if A092040's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A092040's dividend payments have been increasing.

Dividend Yield vs Market

Amicogen Dividend Yield vs Market
How does A092040 dividend yield compare to the market?
SegmentDividend Yield
Company (A092040)0%
Market Bottom 25% (KR)1.2%
Market Top 25% (KR)3.9%
Industry Average (Biotechs)0.5%
Analyst forecast (A092040) (up to 3 years)n/a

Notable Dividend: Unable to evaluate A092040's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A092040's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: A092040 is not paying a notable dividend for the KR market.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A092040 has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 06:44
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amicogen, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mujinn LeeCape Investment & Securities Co., Ltd.
So-Eun ChoiLS Securities Co., Ltd.